Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Clinical trial NCT05350072 · COMPLETED

Trial details

NCT number: NCT05350072
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Sjogren Syndrome

Start date: 2022-07-28
Primary completion: 2025-05-07
Enrollment: 275

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.